SAN DIEGO, Aug. 29, 2018 /PRNewswire/ -- Mirati
Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted
oncology company, will participate in two panel discussions, at the
2018 Citi Biotech Conference in Boston. Charles M.
Baum, M.D., Ph.D., President and Chief Executive Officer
will represent Mirati at the event.
- "Targeted Therapies Oncology - Aiming for the Bull's Eye" Panel
on Wednesday, September
5th at 3:15 p.m.
ET/12:15 p.m. PT
- "Landscape in Immuno-Oncology and Bi-Specific Antibodies" Panel
on Thursday, September 6th at 9:00 a.m. ET/ 6:00 a.m.
PT
The webcasts will be available through the "Investors" section
of www.mirati.com, and a replay of the webcasts will be made
available for 90 days following the event.
About Mirati Therapeutics
Mirati Therapeutics, Inc. is a clinical-stage oncology company
developing product candidates to address the genetic, epigenetic
and immunological promoters of cancer. Our precision oncology
clinical programs utilize next-generation genomic testing to
identify and select cancer patients who we believe would be most
likely to benefit from targeted drug treatment. In immuno-oncology,
we are advancing clinical programs where our product candidates
have the potential to improve the immune environment of tumor cells
and may enhance and expand the efficacy of existing cancer
immunotherapy medicines when given in combination. Our pre-clinical
programs include potentially first-in-class and best-in-class
product candidates specifically designed to address mutations and
tumors where few treatment options exist. We approach each of our
discovery and development programs with a singular focus: to
translate our deep understanding of the molecular drivers of cancer
into better therapies and better outcomes for patients. For more
information, visit www.mirati.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/mirati-therapeutics-to-participate-in-oncology-panels-at-the-2018-citi-biotech-conference-300704377.html
SOURCE Mirati Therapeutics, Inc.